Journal of Clinical Endocrinology & Metabolism, Vol 77, 1090-1094, Copyright © 1993 by Endocrine Society

ARTICLES

Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy

JC Sisson, RJ Ackermann, MA Meyer and RL Wahl
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0028.

A patient developed a pulmonary metastasis from papillary thyroid carcinoma. This tumor concentrated relatively little 131I, but sufficient 18F-fluoro-2-deoxy-D-glucose (FDG) to be quantified and imaged by positron emission tomography. The uptake of FDG was lower on positron emission tomographic images after T4 therapy and when the serum TSH concentration was reduced to the low normal range. It may be possible to use decreases in FDG uptake by thyroid cancers, which represent declines in metabolism by the tumors, to indicate the optimum doses of T4 treatment for patients with these neoplasms. In addition, the ratio of tumor to background radioactivity was higher for FDG than for the flow agent 201Tl, so that studies with FDG may be a useful scintigraphic method for locating thyroid cancers when radioiodine imaging is unsatisfactory.

This article has been cited by other articles:

				S. Leboulleux, P. R. Schroeder, N. L. Busaidy, A. Auperin, C. Corone, H. A. Jacene, M. E. Ewertz, C. Bournaud, R. L. Wahl, S. I. Sherman, et al. Assessment of the Incremental Value of Recombinant Thyrotropin Stimulation before 2-[18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Imaging to Localize Residual Differentiated Thyroid Cancer J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1310 - 1316. [Abstract] [Full Text] [PDF]

				D. Blaser, S. Maschauer, T. Kuwert, and O. Prante In Vitro Studies on the Signal Transduction of Thyroidal Uptake of 18F-FDG and 131I-Iodide J. Nucl. Med., August 1, 2006; 47(8): 1382 - 1388. [Abstract] [Full Text] [PDF]

				H. Palmedo, J. Bucerius, A. Joe, H. Strunk, N. Hortling, S. Meyka, R. Roedel, M. Wolff, E. Wardelmann, H.-J. Biersack, et al. Integrated PET/CT in Differentiated Thyroid Cancer: Diagnostic Accuracy and Impact on Patient Management J. Nucl. Med., April 1, 2006; 47(4): 616 - 624. [Abstract] [Full Text] [PDF]

				L. Hooft, A. A. M. van der Veldt, P. J. van Diest, O. S. Hoekstra, J. Berkhof, G. J. J. Teule, and C. F. M. Molthoff [18F]Fluorodeoxyglucose Uptake in Recurrent Thyroid Cancer Is Related to Hexokinase I Expression in the Primary Tumor J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 328 - 334. [Abstract] [Full Text] [PDF]

				K. Pacak, G. Eisenhofer, and D. S. Goldstein Functional Imaging of Endocrine Tumors: Role of Positron Emission Tomography Endocr. Rev., August 1, 2004; 25(4): 568 - 580. [Abstract] [Full Text] [PDF]

				B. B. Chin, P. Patel, C. Cohade, M. Ewertz, R. Wahl, and P. Ladenson Recombinant Human Thyrotropin Stimulation of Fluoro-D-Glucose Positron Emission Tomography Uptake in Well-Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 91 - 95. [Abstract] [Full Text] [PDF]

				N Khan, N Oriuchi, T Higuchi, H Zhang, and K Endo PET in the follow-up of differentiated thyroid cancer Br. J. Radiol., October 1, 2003; 76(910): 690 - 695. [Abstract] [Full Text] [PDF]

				S. Szakall Jr., O. Esik, G. Bajzik, I. Repa, G. Dabasi, I. Sinkovics, P. Agoston, and L. Tron 18F-FDG PET Detection of Lymph Node Metastases in Medullary Thyroid Carcinoma J. Nucl. Med., January 1, 2002; 43(1): 66 - 71. [Abstract] [Full Text] [PDF]

				B. O. Helal, P. Merlet, M.-E. Toubert, B. Franc, C. Schvartz, H. Gauthier-Koelesnikov, A. Prigent, and A. Syrota Clinical Impact of 18F-FDG PET in Thyroid Carcinoma Patients with Elevated Thyroglobulin Levels and Negative 131I Scanning Results After Therapy J. Nucl. Med., October 1, 2001; 42(10): 1464 - 1469. [Abstract] [Full Text] [PDF]

				L. Hooft, O. S. Hoekstra, W. Deville, P. Lips, G. J. J. Teule, M. Boers, and M. W. van Tulder Diagnostic Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Follow-Up of Papillary or Follicular Thyroid Cancer J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3779 - 3786. [Abstract] [Full Text] [PDF]

				T. Shiga, E. Tsukamoto, K. Nakada, K. Morita, T. Kato, M. Mabuchi, K. Yoshinaga, C. Katoh, Y. Kuge, and N. Tamaki Comparison of 18F-FDG, 131I-Na, and 201Tl in Diagnosis of Recurrent or Metastatic Thyroid Carcinoma J. Nucl. Med., March 1, 2001; 42(3): 414 - 419. [Abstract] [Full Text]

				B. Schluter, K. H. Bohuslavizki, W. Beyer, M. Plotkin, R. Buchert, and M. Clausen Impact of FDG PET on Patients with Differentiated Thyroid Cancer Who Present with Elevated Thyroglobulin and Negative 131I Scan J. Nucl. Med., January 1, 2001; 42(1): 71 - 76. [Abstract] [Full Text] [PDF]

				F. Moog, R. Linke, N. Manthey, R. Tiling, P. Knesewitsch, K. Tatsch, and K. Hahn Influence of Thyroid-Stimulating Hormone Levels on Uptake of FDG in Recurrent and Metastatic Differentiated Thyroid Carcinoma J. Nucl. Med., December 1, 2000; 41(12): 1989 - 1995. [Abstract] [Full Text] [PDF]

				F. Grunwald and H.-J. Biersack FDG PET in Thyroid Cancer: Thyroxine or Not? J. Nucl. Med., December 1, 2000; 41(12): 1996 - 1998. [Full Text] [PDF]

				W. Wang, H. Macapinlac, S. M. Larson, S. D. J. Yeh, T. Akhurst, R. D. Finn, J. Rosai, and R. J. Robbins [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Localizes Residual Thyroid Cancer in Patients with Negative Diagnostic 131I Whole Body Scans and Elevated Serum Thyroglobulin Levels J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2291 - 2302. [Abstract] [Full Text]